Cosmos Health unit secures orders for 253,657 units

Cosmos Health Inc. announced that its wholly-owned subsidiary, Cana Laboratories, has secured new contract manufacturing orders totaling 253,657 units from Nassington and Verisfield. The orders encompass a diverse range of medicines and pharmaceutical products, reinforcing the demand for Cana's manufacturing capabilities and the strength of Cosmos Health's vertically integrated platform.

Order Details

The new contract manufacturing orders include the following products:

Product	Presentation
Gritse oral solution	0.4 mg/ml (bottle x 150 ml)
Gritse forte oral solution	2 mg/ml (bottle x 50 ml)
Gritse forte oral solution	4 mg/ml (bottle x 50 ml)
Fungofort cutaneous spray, solution	30 ml
Paco-4 tablets	250+250+65+35 mg
Dexamethasone	2 mg/5 ml, 50 ml and 150 ml bottle and oral solution presentations
Foproct rectal cream	1 + 1.5%

Strategic Impact

Greg Siokas, CEO of Cosmos Health, stated that these orders reflect the demand for Cana's contract manufacturing capabilities. He emphasized that deepening relationships with established pharmaceutical partners across a broad range of products supports the company's goal of building a diversified manufacturing business. This strategy is aimed at creating long-term value for shareholders.

Company Background

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), the company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes pharmaceuticals and parapharmaceuticals through its subsidiaries in Greece and the UK.

Cosmos Health Inc. has reported that its proprietary antiseptic brands, C-Scrub and C-Sept, have generated over $1.5 million in combined annualized sales across the United Kingdom and Greece. The company is targeting a significant expansion into additional European Union markets, with goals to reach $7.4 million in revenue and $5.3 million in gross profit within three years.

The brands currently achieve gross margins above 70%, making them a high-margin pillar within Cosmos Health's portfolio. Nearly half of the sales originate from the United Kingdom, where C-Scrub holds close to 900 ratings on Amazon, predominantly 5-star, and is available via Tesco and Superdrug. In Greece, momentum is driven through the hospital channel, reflecting adoption among healthcare professionals.

Cosmos Health has outlined a three-year growth trajectory for C-Scrub and C-Sept, supported by continued expansion in existing markets and entry into new EU countries. The company projects that gross margins will remain consistent at approximately 72%.

Three-Year Financial Targets

Year	Revenue (Approx.)	Gross Profit (Approx.)
2026	$2.5 million	$1.8 million
2027	$4.2 million	$3.0 million
2028	$7.4 million	$5.3 million

Strategic Expansion Initiatives

To achieve these targets, Cosmos Health is pursuing entry into hospital and clinical settings, leveraging the suitability of its antiseptic products for professional hygiene. Additionally, the company is extending C-Scrub into the animal healthcare market, broadening its addressable market to include veterinary use. Management believes these initiatives may lead to an upward revision of the current targets.

Greg Siokas, CEO of Cosmos Health, stated that the company is building a high-margin antiseptics business with significant competitive advantages. He highlighted that the brands are fast becoming a flagship growth engine and a meaningful contributor to revenue, cash flow, and long-term shareholder value as the company expands across the EU and into animal healthcare.